Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Non-Controlled, Open-Label, Multicenter, Study of Immune Tolerance Induction Performed With rFVIIIFc Within a Timeframe of 60 Weeks in Severe Haemophilia A Patients With Inhibitors Who Have Failed Previous Immune Tolerance Induction Therapies

Trial Profile

A Non-Controlled, Open-Label, Multicenter, Study of Immune Tolerance Induction Performed With rFVIIIFc Within a Timeframe of 60 Weeks in Severe Haemophilia A Patients With Inhibitors Who Have Failed Previous Immune Tolerance Induction Therapies

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Jan 2019

At a glance

  • Drugs Efmoroctocog alfa (Primary)
  • Indications Haemophilia A
  • Focus Therapeutic Use
  • Acronyms ReITIrate
  • Sponsors Swedish Orphan Biovitrum
  • Most Recent Events

    • 15 Jan 2019 Status changed from recruiting to active, no longer recruiting.
    • 12 Oct 2018 Planned End Date changed from 1 Dec 2020 to 1 Sep 2020.
    • 12 Oct 2018 Planned primary completion date changed from 31 Dec 2019 to 31 Oct 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top